Payment overview · 2025
General Payments
$3,767.66
177 reported records · 28 companies
Healthcare provider profile · identity verified
Jack Manuel Englert, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HUNTSVILLE, AL · NPI 1558324186
Verified facts
What the public records show
CMS Open Payments records show Jack Manuel Englert, M.D. received $3,767.66 in general payments during 2025 across 177 reported records.
ABBVIE INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $657.99 | 17.5% | 25 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $380.07 | 10.1% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $375.87 | 10.0% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $374.95 | 9.9% | 18 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $210.70 | 5.6% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $179.01 | 4.8% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $152.50 | 4.0% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $147.33 | 3.9% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $144.90 | 3.9% | 10 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $141.25 | 3.8% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $135.12 | 3.6% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.35 | 2.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $95.64 | 2.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $92.64 | 2.5% | 4 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $84.62 | 2.2% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $65.79 | 1.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.15 | 1.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $58.48 | 1.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $42.86 | 1.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.38 | 1.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.54 | 1.0% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $35.36 | 0.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.78 | 0.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.29 | 0.8% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $27.65 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.17 | 0.6% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $20.88 | 0.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.39 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,767.66 | 177 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $440.05 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $353.25 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $292.53 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $272.02 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $234.43 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $217.94 | 13 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $210.70 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $196.52 | 13 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $152.50 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $147.33 | 8 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $144.90 | 10 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $141.44 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $141.25 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $135.12 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.71 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $104.23 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $100.35 | 10 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $84.62 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $78.79 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.48 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $65.79 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.15 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.04 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $58.48 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $42.86 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.54 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $30.78 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 64 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
78 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 601 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 482 | 145 |
| Gabapentin | Gabapentin | 353 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 99 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 261 | 58 |
| Metformin Hcl Er | Metformin Hcl | 250 | 75 |
| Alprazolam | Alprazolam | 231 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 73 |
| Omeprazole | Omeprazole | 206 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 53 |
| Famotidine | Famotidine | 169 | 65 |
| Tramadol Hcl | Tramadol Hcl | 151 | 36 |
| Sertraline Hcl | Sertraline Hcl | 139 | 39 |
| Meloxicam | Meloxicam | 137 | 50 |
| Prednisone | Prednisone | 135 | 71 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 134 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 44 |
| Lisinopril | Lisinopril | 123 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 37 |
| Irbesartan | Irbesartan | 105 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 32 |
| Terazosin Hcl | Terazosin Hcl | 98 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 30 |
| Clonazepam | Clonazepam | 84 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 30 |
| Losartan Potassium | Losartan Potassium | 82 | 26 |
| Eliquis | Apixaban | 78 | 20 |
| Jardiance | Empagliflozin | 78 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 22 |
| Potassium Chloride | Potassium Chloride | 77 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 73 | 20 |
| Lorazepam | Lorazepam | 68 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Valsartan | Valsartan | 67 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 20 |
| Methocarbamol | Methocarbamol | 65 | 34 |
| Synthroid | Levothyroxine Sodium | 64 | 18 |
| Allopurinol | Allopurinol | 59 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 21 |
| Simvastatin | Simvastatin | 59 | 17 |
| Mirtazapine | Mirtazapine | 58 | 14 |
| Farxiga | Dapagliflozin Propanediol | 55 | 12 |
| Pregabalin | Pregabalin | 55 | 15 |
| Trazodone Hcl | Trazodone Hcl | 55 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 54 | 14 |
| Celecoxib | Celecoxib | 53 | 19 |
| Azithromycin | Azithromycin | 51 | 44 |
| Glipizide Er | Glipizide | 49 | 17 |
| Ramipril | Ramipril | 49 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 27 |
| Estradiol | Estradiol | 46 | 19 |
| Memantine Hcl | Memantine Hcl | 46 | 13 |
| Diazepam | Diazepam | 45 | suppressed |
| Cephalexin | Cephalexin | 43 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 14 |
| Olanzapine | Olanzapine | 42 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 41 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Furosemide | Furosemide | 38 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 29 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Telmisartan | Telmisartan | 36 | 12 |
| Valacyclovir | Valacyclovir Hcl | 36 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 33 | 12 |
| Finasteride | Finasteride | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 11 |
| Carvedilol | Carvedilol | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 29 |
| Ozempic | Semaglutide | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Nabumetone | Nabumetone | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 23 | 11 |
| Levofloxacin | Levofloxacin | 23 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Clotrimazole | Clotrimazole | 22 | 17 |
| Glimepiride | Glimepiride | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | 14 |
| Colchicine | Colchicine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 12 |
| Torsemide | Torsemide | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | 14 |
| Cefdinir | Cefdinir | 15 | 15 |
| Halobetasol Propionate | Halobetasol Propionate | 15 | 11 |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Etodolac | Etodolac | 14 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,767.66 · 177 records | ABBVIE INC. | AIRSUPRA, ARISTADA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JATENZO, KISUNLA, Kerendia, Korlym, LOREEV XR, LYBALVI, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, Sunosi, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error